![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/08/Medicom-podcast.jpg)
EHA 2020
![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/08/EHA-Cover-230x300.png)
Read the full Report (pdf)
European Haematology Association 11 to 21 June 2020
Featured articles
![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/08/Medicom-podcast.jpg)
![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/09/HEMA_Photo-Prof.-Gert-van-Ossenkoppele.jpeg)
Letter from the Editor
CONTENTS
Online First
Myeloid
VIALE-A: newly diagnosed chemo-ineligible AML
OS benefit in VIALE-C trial
![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/09/EHA2020-MCR-C3-4-e1609862599633-1024x580.png)
DEC10-VEN superior to intensive chemotherapy in high-risk AML
Magrolimab plus azacitidine: good ORR in MDS/AML
Asciminib monotherapy in Ph+ CML: major molecular responses
CML TKI interruption: Swedish registry results
Patients with lower-risk MDS benefit from imetelstat
Better outcomes adding enasidenib to azacitidine in mIDH2-AML
Lymphoid
PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma
Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma
![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/09/EHA2020-MCR-C3-9-e1609924865171-1024x316.png)
Promising first-in-human trial of epcoritamab in B-NHL
Two trials: acalabrutinib in CLL
Zanubrutinib versus ibrutinib in Waldenström macroglobulinaemia
![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/09/EHA2020-MCR-C3-11-e1609925374603-1024x922.png)
Deep responses in R/R CLL with venetoclax monotherapy
MRD assessment post-CAR-T predicts ALL allo-HSCT bridging
Plasma Cell Dyscrasias
Daratumumab for light-chain amyloidosis
Isatuximab triplet improves PFS in R/R MM
![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/09/EHA2020-MCR-C3-14-e1599652252197-1024x437.png)
Initial results from CAR-T cell therapy in MM: KarMMa
Graft-Versus-Host Disease
GRAVITAS-301: improved complete aGVDH response
Ruxolitinib improves steroid-refractory aGVHD across subtypes
Benign Haematology
Endothelial damage in COVID-19
Paroxysmal nocturnal haemoglobinuria treatment with pegcetacoplan
Mitapivat, a pyruvate kinase-R activator, in SCD is safe with early efficacy results
SCD LentiGlobin gene therapy: new data on VOC and ACS
Paediatric Haematology
Venetoclax + navitoclax promising for R/R ALL or LL
![](https://conferences.medicom-publishers.com/wp-content/uploads/2020/08/EHA2020-MCR-C3-19-e1598610643819-1024x383.png)